[Pneumococcal vaccination coverage in at-risk children in Catalonia].

Enferm Infecc Microbiol Clin

Servicio de Medicina Preventiva y Epidemiología, Hospital Universitario Vall d'Hebron, Barcelona, España.

Published: November 2015

Introduction: The public health system in Catalonia only funds pneumococcal vaccination in paediatrics for children at-risk. The aim of this study was to determine pneumococcal vaccination coverage and its association with age, sociodemographic factors and other variables.

Material And Method: Descriptive cross-sectional study of children aged between 2 months and 15 years old assigned to primary care centres in Catalonia and with diseases that are included for pneumococcal vaccine in the official vaccination program. The information on vaccination status and study variables were obtained from data registered in the electronic medical records in the primary care centres. An analysis was made of the association between pneumococcal vaccination and demographic and medical variables using bivariate analysis and a multiple logistic regression model. The adjusted odds ratio (aOR), with a confidence interval of 95%, was used to measure the relationships.

Results: Pneumococcal vaccination coverage was 47.7%. Variables which predicted pneumococcal vaccination were: age (aOR: 9.2 [7.9-10.7] in children 2 months-2 years old; aOR 8.1 [7.0-9.3] in children 3-5 years; aOR: 4.6 [4.0-5.2] in children 6-10 years), Spanish nationality (aOR: 3.9 [3.5-4.3]), correct immunisation according to systematic immunisation schedule (aOR: 2.5 [2.1-3.0]), and number of risk conditions (aOR: 3.2 [2.5-4.1] in children with 2 or more conditions).

Conclusions: Pneumococcal vaccination coverage in children with risk conditions is low in Catalonia. Strategies need to be implemented to increase coverage.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eimc.2015.01.003DOI Listing

Publication Analysis

Top Keywords

pneumococcal vaccination
24
vaccination coverage
16
children
8
vaccination
8
primary care
8
care centres
8
years aor
8
risk conditions
8
pneumococcal
7
aor
7

Similar Publications

Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally.

Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally.

View Article and Find Full Text PDF

Background: The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for standalone or sequential use in the elderly in many countries to prevent pneumococcal disease, making it crucial to assess vaccine response and long-term persistence.

Purpose: We aimed to describe the trajectories of circulating antibody levels to the PPSV23 in the elderly following immunization.

Methods: Eligible individuals aged 65 to 70 years were enrolled and vaccinated with one dose of PPSV23.

View Article and Find Full Text PDF

Influenza and pneumococcal vaccinations play a crucial role in disease prevention among older adults and are recommended to older adults aged 60 years and over in China, but the vaccination rates are suboptimal. Behavioral spillover indicates that a change in one behavior may lead to changes in other related behaviors. Based on the Behavioral Spillover Theory, this study aimed to investigate the association between influenza vaccination history and pneumococcal vaccination intention, as well as the mediating role of negative attitudes toward general vaccination among older adults in China.

View Article and Find Full Text PDF

Adult vaccinations against respiratory infections.

Expert Rev Anti Infect Ther

January 2025

Ciber de Enfermedades Respiratorias (Ciberes) Barcelona, Spain.

Introduction: Lower respiratory infections have a huge impact on global health, especially in older individuals, immunocompromised people, and those with chronic comorbidities. The COVID-19 pandemic highlights the importance of vaccination. However, there are lower rates of vaccination in the adult population that are commonly due to a missed opportunity to vaccinate.

View Article and Find Full Text PDF

October 2024 ACIP Meeting Update: Influenza, COVID-19, RSV and Other Vaccines.

Pediatrics

January 2025

Department of Pediatrics, University of Cincinnati College of Medicine and Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati OH.

The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts that provides advice to the Centers for Disease Control and Prevention, normally meets 3 times per year to develop US vaccine recommendations. The ACIP met October 23-24, 2024, to discuss influenza vaccines, chikungunya vaccines, coronavirus disease (COVID-19) vaccines, RSV immunizations, meningococcal vaccines, human papillomavirus (HPV) vaccines, pneumococcal vaccines, and adult and child/adolescent immunization schedule revisions. This update summarizes the proceedings of these meetings, with an emphasis on topics that are most relevant to the pediatric population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!